Chemistry:NNZ-2591
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | Cyclo(L-glycyl-L-2-allylproline) |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C10H14N2O2 |
| Molar mass | 194.234 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
NNZ-2591 is a synthetic analog of cyclic glycine-proline and experimental drug developed for Angelman syndrome, Phelan-McDermid syndrome, Pitt Hopkins syndrome,[1][2] and Prader-Willi syndrome.[3]
References
- ↑ Markati, Theodora; Duis, Jessica; Servais, Laurent (3 July 2021). "Therapies in preclinical and clinical development for Angelman syndrome". Expert Opinion on Investigational Drugs 30 (7): 709–720. doi:10.1080/13543784.2021.1939674.
- ↑ Heussler, Helen S. (March 2021). "Emerging Therapies and challenges for individuals with Angelman syndrome". Current Opinion in Psychiatry 34 (2): 123–128. doi:10.1097/YCO.0000000000000674. ISSN 0951-7367. https://journals.lww.com/co-psychiatry/abstract/2021/03000/emerging_therapies_and_challenges_for_individuals.9.aspx.
- ↑ "An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) (PWS-001) NCT05879614". https://clinicaltrials.gov/study/NCT05879614.
 |  |
